Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
{{output}}
A desirable property of any dose-escalation strategy for phase I oncology trials is coherence: if the previous patient experienced a toxicity, a higher dose is not recommended for the next patient; similarly, if the previous patient did not experience a toxici... ...
